- BriaCell
Therapeutics Corp. is working to develop the first off-the-shelf
personalized immunotherapy for advanced breast cancer
- Clinical
data reveals an excellent safety profile and potent anti-tumor activity
for Bria-IMT in advanced breast cancer patients
- Combination
study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab)
in advanced breast cancer patients is ongoing
- Symposium
covers the latest research on experimental biology, etiology, prevention,
diagnosis and treatment of breast cancer and premalignant breast disease
- International
audience from over 90 countries includes researchers, health
professionals, physicians, oncologists and those with a special interest
in breast cancer
An immuno-oncology focused biotechnology company, BriaCell Therapeutics
Corp. (OTCQB: BCTXF) (TSX.V: BCT) will present details of its proprietary
targeted immunotherapy technology in patients with advanced breast cancer
during a poster session of the 2018 San Antonio Breast Cancer Symposium, scheduled for
December 4-8 in San Antonio, Texas. Highlights of the company’s data on
Bria-IMT as a monotherapy, demonstrating positive proof-of-concept and an
initial assessment of safety and tolerability for Bria-IMT in combination with
pembrolizumab (KEYTRUDA, manufactured by Merck & Co., Inc.) in advanced
breast cancer patients, will be presented.
Presenting the poster will be Saveri Bhattacharya,
DO, (http://ibn.fm/K2lpm)
assistant professor of medical oncology at Thomas Jefferson University (http://ibn.fm/6UqCV), researcher
at the NCI-designated Sidney Kimmel Cancer Center (http://ibn.fm/uapyF) at
Jefferson Health (http://ibn.fm/MJJVW)
and principal investigator (PI) of the study. BriaCell’s scientific team will
be available to answer questions during the poster presentation.
Identified as poster no. 212 during the treatment
immunotherapy (clinical) session and with the title “Initial safety and
efficacy of a phase I/IIa trial of a modified whole tumor cell targeted
immunotherapy in patients with advanced breast cancer,” BriaCell’s poster
presentation is slated for Thursday, December 6, from 7:30 am to 9:00 am CT at
the Henry B. Gonzalez Convention Center at 900 E. Market Street in San Antonio,
Texas. The combination study is also listed on ClinicalTrials.gov with the
National Institutes of Health as NCT03328026.
Improving the efficacy, safety and cost of care for those
who are annually diagnosed with breast cancer continues to be at the forefront
of medical research. An estimated 266,120 new cases of breast cancer are
projected to be diagnosed in U.S. women during 2018, according to the National
Cancer Institute (NCI) (http://ibn.fm/cUSKe).
Female breast cancer represents 15.3 percent of all new cancer cases in the
U.S., with nearly 41,000 women expected to die of the disease in 2018,
according to the NCI. Breast cancer is identified as the most commonly
occurring cancer in women around the globe and the second most common cancer
overall, according to the World Cancer Research Fund International (http://ibn.fm/sVNYK).
”Early clinical findings of BriaCell’s novel, personalized
immunotherapy treatment approach is generating great excitement,” Dr. Bill
Williams, BriaCell’s president and CEO, noted in a news release.
“Bria-IMT has demonstrated positive proof-of-concept in
advanced breast cancer, and we will delve into these data in San Antonio’s Breast
Cancer conference which is a key oncology conference attended by leading
scientists and oncologists worldwide. We have firm grounds to believe the
anti-tumor effects of Bria-IMT can be greatly improved by combination with
KEYTRUDA,” Williams continued (http://ibn.fm/O9cgn). “As we advance our technology and
generate additional data, we will continue to discuss our novel therapeutic
approach with potential partners to explore additional combinations. With the
potential for a safe and effective treatment option for advanced breast cancer
patients, we are committed to developing the shortest possible pathway to make
these therapies available to these patients.”
Following the presentation at the symposium, copies of the
abstract and poster will be available on www.BriaCell.com/Investor-Relations/Presentations
For more information, visit the company’s website at www.BriaCell.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment